{
  "symbol": "VCYT",
  "company": "Veracyte, Inc.",
  "generated_at": "2026-06-24T07:36:54.014Z",
  "event_count": 3,
  "events": [
    {
      "type": "pipeline_event",
      "ts": "2026-06-05T02:01:57.625Z",
      "stage": "analyst",
      "outcome": "skip",
      "reason": "Score of 23/100 reflects full valuation, overbought technicals, and zero smart-money conviction. Anti-signal gates for low liquidity and pump/dump patterns mandate a skip, and the recent ASCO catalysts are already fully priced in with no asymmetric upside or income structure edge.",
      "trigger": "[insider_cluster_universe] 6 Form 4 filings in last 14 days · at least one open-market P/S trade verified",
      "source": "idle_hunter"
    },
    {
      "type": "analyst_decision",
      "ts": "2026-06-05T02:01:57.592Z",
      "skip": true,
      "reason": "Score of 23/100 reflects full valuation, overbought technicals, and zero smart-money conviction. Anti-signal gates for low liquidity and pump/dump patterns mandate a skip, and the recent ASCO catalysts are already fully priced in with no asymmetric upside or income structure edge.",
      "score": 23,
      "breakdown": {
        "smart_money": 0,
        "options_flow": 0,
        "catalyst": 15,
        "mispricing": 0,
        "quality": 5,
        "technical": 3
      },
      "debug_path": "drafts/2026-06-05-VCYT.analyst.debug.json"
    },
    {
      "type": "scout_dossier",
      "ts": "2026-06-05T02:01:09.866Z",
      "summary": "Veracyte presents a well-functioning diagnostics company with strong fundamentals and multiple positive catalysts — landmark Phase III ASCO data (OPTIMA for Prosigna, ENZAMET for Decipher Prostate), commercial US launch of Prosigna, and Medicare coverage secured for TrueMRD. However, the investigation trigger referencing insider open-market P/S clustering does not hold up under scrutiny: all 30 recent Form 4 filings are routine — RSU vesting at $0 strike (code A), tax-withholding sells (code F), or pre-scheduled Rule 10b5-1 plan sales (code S). Zero true discretionary open-market purchases from any insider. The stock is also near 52-week high, RSI=74.4 (overbought), and forward P/E of ~26x with EV/EBITDA of ~34x represents full valuation in a high-quality but richly priced name.",
      "verdict": "range_bound_or_income",
      "confidence": 5,
      "tool_calls": 23,
      "walltime_min": 20,
      "debug_path": "dossiers/2026-06-05-VCYT.scout.debug.json"
    }
  ],
  "lessons": [],
  "chart_signal": {
    "ticker": "VCYT",
    "call": "BUY",
    "confidence": 4,
    "score": 7,
    "factors": {
      "above_200dma": "+2",
      "above_50dma": "+1",
      "momentum_strong_up": "+2 (68.1%)",
      "rsi_overbought": "-1 (72.1)",
      "macd_above_signal": "+1",
      "recent_macd_bullish_cross": "+1 (2d ago)",
      "near_52w_high": "+1 (0.0% from high)"
    },
    "summary": "BUY (score +7) · 12-1 mom 68.1% · RSI 72.1 · above_both · 0.0% from high",
    "last_close": 53.79,
    "one_month_ago_close": 45.19,
    "twelve_month_ago_close": 26.88,
    "twelve_one_momentum_pct": 68.12,
    "rsi_14": 72.1,
    "ma_stack": "above_both",
    "from_period_high_pct": 0,
    "period_high": 53.79,
    "price_targets": {
      "bear": 37,
      "fair": 48.17,
      "bull": 61.86,
      "bear_return_pct": -31.2,
      "fair_return_pct": -10.4,
      "bull_return_pct": 15,
      "method": "street_targets ⨯ chart_floors",
      "street": {
        "target_low": 37,
        "target_mean": 49.1,
        "target_high": 57,
        "analyst_count": 10
      }
    },
    "generated_at": "2026-06-24T07:36:54.009Z"
  }
}